Wednesday, June 10, 2026

Patent intelligence · US

US 2015366947

A Method of Purifying Therapeutic Proteins

granted A61K 38/ 36 A I
Status granted
Pipeline programs 6
Years to expiry 10
Applicant portfolio 25
Patent details — US 2015366947

Quick answer

US 2015366947 (A Method of Purifying Therapeutic Proteins) is held by CSL LTD [AU]. Status: granted. Granted Dec 24, 2015. Expires Dec 19, 2035 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
CSL LTD [AU]
Grant date
Expiration
Claims
CPC classes
A61K 38/ 36 A I

More from CSL LTD [AU]

Related pharmaceutical patents in our USPTO index.

  1. WO 2022258590

    PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN

    PREVIPHARMA CONSULTING GMBH [DE] · Expires Dec 10, 2042

    granted
  2. CA 3198740

    METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS

    CSL BEHRING GMBH [DE] · Expires May 22, 2042

    granted
  3. AU 2017305856

    Pharmaceutical formulations of C1 esterase inhibitor

    CSL BEHRING GMBH [DE] · Expires Mar 16, 2039

    granted
  4. DK 2928905

    FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER

    CSL BEHRING GMBH [DE] · Expires Mar 6, 2039

    granted
  5. CA 3072003

    PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND

    CSL BEHRING GMBH [DE] · Expires Feb 23, 2039

    granted
  6. US 2018264111

    PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS

    CSL BEHRING GMBH AG [CH] · Expires Sep 15, 2038

    granted
  7. CA 3046406

    PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES

    CSL BEHRING GMBH [DE] · Expires Aug 11, 2038

    granted
  8. CA 3034568

    PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE

    CSL BEHRING GMBH [DE] · Expires Feb 24, 2038

    granted

Frequently asked questions

What is US patent 2015366947?

US 2015366947 (A Method of Purifying Therapeutic Proteins) is held by CSL LTD [AU]. Status: granted. Granted Dec 24, 2015. Expires Dec 19, 2035 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2015366947?

CSL LTD [AU] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2015366947 expire?

Our index shows an expiration date of Dec 19, 2035 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.